馬來西亞洽購科興生物及康希諾生物等新冠疫苗
馬來西亞首相慕尤丁表示,已經簽約購買640萬劑英國藥廠阿斯利康(AZN.US)的新冠疫苗,並與科興生物、康希諾生物(06185.HK)及俄羅斯加馬列亞研究中心(Gamaleya Institute)的購買疫苗談判進入最後階段。
馬來西亞上月已購買1,280萬劑輝瑞疫苗,同時亦加入由世衛(WHO)支持的新冠肺炎疫苗實施計劃(COVAX)。慕尤丁表示,政府取得足夠涵蓋四成人口的疫苗,希望最終能購買足夠八成人口使用的疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.